The Centers for Medicare and Medicaid Services should flesh out and reintroduce its proposal to allow manufacturers to report multiple “best prices” in Medicaid before moving ahead with it as a means of facilitating value-based purchasing, biopharma manufacturers urged in recent comments to the agency.
Released in mid-June, the proposal is meant to remove some of the obstacles to value-based purchasing in the commercial market that are caused by Medicaid best price reporting requirements